🇺🇸 LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN in United States

152 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Death — 27 reports (17.76%)
  2. Malignant Neoplasm Progression — 21 reports (13.82%)
  3. Anaemia — 16 reports (10.53%)
  4. Fatigue — 16 reports (10.53%)
  5. Hot Flush — 15 reports (9.87%)
  6. Erectile Dysfunction — 14 reports (9.21%)
  7. Hormone-Refractory Prostate Cancer — 14 reports (9.21%)
  8. Drug Ineffective — 10 reports (6.58%)
  9. Thrombocytopenia — 10 reports (6.58%)
  10. Overdose — 9 reports (5.92%)

Source database →

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN in United States?

Marketing authorisation holder not available in our data.